Boston Scientific Corporation (BSX) fundamentals from SEC filings — revenue $20.1B, net margin 14.4%, diluted EPS $1.94 in FY2025. Revenue, margins, EPS and free cash flow, year by year.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B |
| Net income | $1.0B | $698.0M | $1.6B | $1.8B | $2.9B |
| Net margin | 8.8% | 5.5% | 11.2% | 11.0% | 14.4% |
| Diluted EPS | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 |
| Free cash flow | $1.3B | $938.0M | $1.8B | $2.6B | $3.7B |
Figures are as reported to the SEC (EDGAR companyfacts), in the filer's own fiscal years.
Sign in to PortfolioX for the full analysis — ten years of history, segment and geographic breakdowns, valuation multiples, analyst estimates and filings. · PortfolioX home